Toggle Main Menu Toggle Search

Open Access padlockePrints

Treatment and management of children with haemolytic uraemic syndrome

Lookup NU author(s): Dr Patrick Walsh, Dr Sally Johnson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved. Haemolytic uraemic syndrome (HUS), comprising microangiopathic haemolytic anaemia, thrombocytopaenia and acute kidney injury, remains the leading cause of paediatric intrinsic acute kidney injury, with peak incidence in children aged under 5 years. HUS most commonly occurs following infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Additionally, HUS can occur as a result of inherited or acquired dysregulation of the alternative complement cascade (atypical HUS or aHUS) and in the setting of invasive pneumococcal infection. The field of HUS has been transformed by the discovery of the central role of complement in aHUS and the dawn of therapeutic complement inhibition. Herein, we address these three major forms of HUS in children, review the latest evidence for their treatment and discuss the management of STEC infection from presentation with bloody diarrhoea, through to development of fulminant HUS.


Publication metadata

Author(s): Walsh PR, Johnson S

Publication type: Article

Publication status: Published

Journal: Archives of Disease in Childhood

Year: 2018

Volume: 103

Issue: 3

Pages: 285-291

Online publication date: 19/02/2018

Acceptance date: 07/08/2017

ISSN (print): 0003-9888

ISSN (electronic): 1468-2044

Publisher: BMJ Publishing Group

URL: https://doi.org/10.1136/archdischild-2016-311377

DOI: 10.1136/archdischild-2016-311377


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share